Activating mutation of KRAS as well as the inactivation of several key tumor suppressor genes, including CDKN2A, p16INK4A, TP53, and SMAD4, are prevalent in the different stages of pancreatic cancers and also in precursor lesions [42–46]. This evidence concerns the gene SMAD4 and pancreatic neoplasm.